-Agreement provides Lilly researchers broad access to HistoRx AQUA(R)
technology for tissue biomarker analysis-
NEW HAVEN, Conn., March 26 /PRNewswire/ -- HistoRx, Inc. announced today that it has signed a three-year agreement with Eli Lilly and Company (NYSE: LLY) to make the HistoRx AQUA(R) technology for tissue biomarker analysis widely available to Lilly researchers and clinicians involved in drug discovery, preclinical research, and clinical development. The agreement extends and significantly expands the scope of the collaboration established by HistoRx and Lilly in 2005 to apply the HistoRx AQUA(R) technology to help advance select Lilly pharmaceutical development programs. Under the new agreement, HistoRx will provide Lilly researchers broad access to the AQUA(R) technology for tissue biomarker analysis, and HistoRx will develop customized AQUA(R) analysis-based immunohistochemical assays for use in Lilly drug discovery and development projects. HistoRx has the option to commercialize the assays and reagents developed during the course of the partnership for clinical use as predictive diagnostics.
HistoRx provides pharmaceutical and biotechnology companies access to
AQUA(R) technology through partnership agreements by which HistoRx works
with the company in applying its hallmark quantitative, multiparametric,
tissue- based biomarker measurement and analysis to drug development
programs, virtually eliminating the subjective interpretation inherent in
conventional immunohistochemical methods. In the course of the partnership,
HistoRx develops AQUA(R) analysis-based diagnostic assays that are linked
to its partners' drugs in development. HistoRx may then commercialize these
assays as prognostic tests or
|SOURCE HistoRx, Inc.|
Copyright©2008 PR Newswire.
All rights reserved